Camzyos (mavacamten) / BMS - LARVOL DELTA

Post-marketing safety signal profile of mavacamten in the FDA adverse event reporting system (FAERS): a disproportionality analysis. (PubMed, Front Pharmacol) - "Mavacamten was associated with expected cardiac safety signals and additional exploratory signals, supporting continued surveillance and careful cardiac monitoring. These hypothesis-generating findings require confirmation in independent data sources."

Adverse events • Journal • P4 data • Atrial Fibrillation • Cardiomyopathy • Cardiovascular • Cataract • Congestive Heart Failure • Heart Failure • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy • Ophthalmology

Coexistence of Hypertrophic Cardiomyopathy and Hereditary Transthyretin Amyloid Cardiomyopathy. (PubMed, JACC Case Rep) - "Dynamic left ventricular outflow tract obstruction does not exclude cardiac amyloidosis. Dual cardiomyopathies should be considered when clinical, imaging, and genetic findings appear discordant."

Journal • Amyloidosis • Cardiac Amyloidosis • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Pulmonary Disease

Midventricular Obstruction Predicts Poor Early Response to Mavacamten in Obstructive Hypertrophic Cardiomyopathy. (PubMed, JACC Heart Fail) - No abstract available

Journal • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy

ODYSSEY_HCM: A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy (clinicaltrials.gov) - P3 | N=580 | Terminated | Sponsor: Bristol-Myers Squibb | Completed ➔ Terminated; Trial terminated because of lack of efficacy in the short term acute phase

Trial termination • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Non-obstructive Hypertrophic Cardiomyopathy

Real-World Study on the Efficacy of Mavacamten in Treating Obstructive Hypertrophic Cardiomyopathy: A Single-Center, Retrospective Cohort Study. (ChiCTR) - P=N/A | N=25 | Not yet recruiting | Sponsor: Xiangya Hospital Central South University; Xiangya Hospital Central South University

New trial • Real-world evidence • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

MEMENTO: A Study to Evaluate Mavacamten Impact on Myocardial Structure in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy (clinicaltrials.gov) - P4 | N=63 | Active, not recruiting | Sponsor: Bristol-Myers Squibb | Trial completion date: Jul 2026 ➔ Jun 2027

Trial completion date • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

ELECTROCARDIOGRAM NORMALIZATION IN A PATIENT WITH HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY TREATED WITH MAVACAMTEN: A CASE REPORT (CHEST 2026) - No abstract available

Case report • Clinical • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

Left Atrial Volume Index, Left Ventricular Outflow Tract Gradient, and Incident Atrial Fibrillation in Hypertrophic Cardiomyopathy. (PubMed, Echocardiography) - "In HCM, LAVI and resting LVOT gradient were each independently associated with incident AF, and neither remained significant when modeled together. LAVI may serve as a practical echocardiographic marker to refine AF risk assessment."

Journal • Retrospective data • Atrial Fibrillation • Cardiomyopathy • Cardiovascular • Hypertension • Hypertrophic Cardiomyopathy

Borderline Significance or Biological Signal? Reinterpreting the ODYSSEY-HCM Trial in Non-obstructive Hypertrophic Cardiomyopathy. (PubMed, Eur Cardiol) - No abstract available

Journal • Review • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Non-obstructive Hypertrophic Cardiomyopathy

BRAVE-HCM: The Therapeutic Value of Mavacamten in Hypertrophic Cardiomyopathy With Mid-to-Apical Left Ventricular Obstruction (clinicaltrials.gov) - P4 | N=132 | Enrolling by invitation | Sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine | Not yet recruiting ➔ Enrolling by invitation | Trial primary completion date: Jul 2026 ➔ Nov 2026

Enrollment open • Real-world evidence • Trial primary completion date • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy

Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy: Is the Story Over? (PubMed, Cardiology) - No abstract available

Journal • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Non-obstructive Hypertrophic Cardiomyopathy

STEP-oHCM: Gradual Tapering or Discontinuation of Beta-Blockers After Stabilization With Mavacamten Therapy (clinicaltrials.gov) - P=N/A | N=286 | Not yet recruiting | Sponsor: First Affiliated Hospital of Wenzhou Medical University

Head-to-Head • New trial • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

Response to: "Comparative hemodynamic effects of mavacamten and septal myectomy in HOCM: important methodological considerations". (PubMed, Cardiovasc Diagn Ther) - No abstract available

Journal • Obstructive Hypertrophic Cardiomyopathy

Comparative hemodynamic effects of mavacamten and septal myectomy in HOCM: important methodological considerations. (PubMed, Cardiovasc Diagn Ther) - No abstract available

Journal • Obstructive Hypertrophic Cardiomyopathy

Effect of cardiac myosin inhibitors on cardiac structure and myocardial fibrosis in obstructive hypertrophic cardiomyopathy: a meta-analysis of cardiac magnetic resonance outcomes. (PubMed, Clin Radiol) - "CMIs have shown efficacy in improving cardiac structure in oHCM. However, the impact on myocardial fibrosis remains unclear."

Journal • Retrospective data • Cardiomyopathy • Cardiovascular • Fibrosis • Hypertrophic Cardiomyopathy • Immunology • Obstructive Hypertrophic Cardiomyopathy

Efficacy and Safety of an LVEF-Guided Mavacamten Dose Up-Titration Strategy in Chinese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (clinicaltrials.gov) - P4 | N=115 | Not yet recruiting | Sponsor: Second Affiliated Hospital of Nanchang University

New P4 trial • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

Efficacy And Safety Of Invasive And Pharmacologic Therapies For Obstructive Hypertrophic Cardiomyopathy: A Systematic Review And Network Meta-analysis Of 8,742 Patients (HFSA 2026) - "Seven randomized controlled trials and 12 observational studies (8,742 adults with oHCM) were included, evaluating mavacamten, aficamten, septal myectomy (SM), alcohol septal ablation (ASA), metoprolol, medical therapy, and placebo. Randomized evidence supports CMIs as the most consistent pharmacologic option for short-term LVOT gradient reduction and symptom improvement in oHCM. Septal reduction therapies provided the greatest relief of provoked obstruction and showed favorable longer-term outcome signals versus medical therapy in observational analyses, although survival inferences remain limited by confounding."

Retrospective data • Review • Acute Kidney Injury • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy • Renal Disease

Gradient Strikes Back! Rebound LVOT Obstruction On Mavacamten [Poster no. 638] (HFSA 2026) - No abstract available

Beyond Lvot Gradients: Hemodynamic Decongestion Demonstrated By Continuous Pa Monitoring After Mavacamten In Obstructive Hcm With Concomitant Nephropathy [Poster no. 421] (HFSA 2026) - No abstract available

Renal Disease

Peak Left Ventricular Outflow Tract Gradient Trajectories During Mavacamten Therapy Stratified By Sarcomere Genetic Burden: A Single-Center Observational Cohort [Poster no. 337] (HFSA 2026) - No abstract available

Clinical • Observational data

Real-world Effectiveness Of Mavacamten Plus Beta-blockers In Obstructive Hypertrophic Cardiomyopathy: A Propensity-matched Cohort Study [Poster no. 309] (HFSA 2026) - No abstract available

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy

Coadministration Of Mavacamten And Tacrolimus In A Kidney Transplant Recipient With Obstructive Hypertrophic Cardiomyopathy [Poster no. 195] (HFSA 2026) - No abstract available

Clinical • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy • Transplantation

Global Real-World Evidence Demonstrates Consistent Effectiveness Of Mavacamten In Obstructive Hypertrophic Cardiomyopathy [Poster no. 162] (HFSA 2026) - No abstract available

Clinical • HEOR • Real-world • Real-world evidence • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy

Effects of Mavacamten on Right Ventricular Mechanics in Hypertrophic Cardiomyopathy: A Single-Center Longitudinal Echocardiographic Study (AHA 2026) - "Abstract is embargoed at this time."

Clinical • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy

CYP2C19 Metabolizer Status and Response to Mavacamten in Obstructive Hypertrophic Cardiomyopathy: A United States Cohort (AHA 2026) - "Abstract is embargoed at this time."

Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • CYP2C19